Involvement of 5-HT2C and 5-HT1A receptors of the basolateral nucleus of the amygdala in the anxiolytic effect of chronic antidepressant treatment

Neuropharmacology

Volumn 79, Issue , 2014, Pages 127-135

  Vicente, Maria Adrielle ^a   Zangrossi Jr , Helio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5 HT2C receptors; Antidepressants and basolateral amygdala; Anxiety; Serotonin

Indexed keywords

6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; FLUOXETINE; IMIPRAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 ANTAGONIST; SEROTONIN 2 AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BASOLATERAL AMYGDALA; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DESENSITIZATION; ELEVATED T-MAZE TEST; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR TEST; LIGHT DARK TRANSITION TEST; LONG TERM CARE; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; AMYGDALOID NUCLEUS; ANIMAL; ANXIETY; DRUG EFFECTS; DRUG THERAPY; EXPLORATORY BEHAVIOR; MAZE TEST; METABOLISM; PANIC; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; AVOIDANCE LEARNING; EXPLORATORY BEHAVIOR; FLUOXETINE; IMIPRAMINE; MALE; MAZE LEARNING; PANIC; PIPERAZINES; PYRAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84890051851     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.11.007     Document Type: Article

References (56)

1. G. Bagdy, M. Graf, Z.E. Anheuer, E.A. Modos, and S. Kantor Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635 Int. J. Neuropsychopharmacol. 4 2001 399 408
2. D.S. Baldwin, S. Waldman, and C. Allgulander Evidence-based pharmacological treatment of generalized anxiety disorder Int. J. Neuropsychopharmacol. 14 2011 697 710
3. B. Bandelow, L. Sher, R. Bunevicius, E. Hollander, S. Kasper, J. Zohar, and H.J. Möller Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care Int. J. Psychiatry Clin. Pract. 16 2012 77 84
4. B. Bert, H. Fink, J. Rothe, J. Walstab, and H. Bönisch Learning and memory in 5-HT(1A)-receptor mutant mice Behav. Brain. Res. 195 2008 78 85
5. G.M. Bressa, S. Marini, and S. Gregori Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam Int. J. Clin. Pharmacol. Res. 7 1987 111 119
6. A. Broocks, N.C. Briggs, T.A. Pigott, J.L. Hill, S.K. Canter, T.J. Tolliver, D. Baldemore, and D.L. Murphy Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment Psychopharmacology (Berl.) 130 1997 91 103
7. D.T. Chalmers, and S.J. Watson Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain - a combined in situ hybridisation/in vitro receptor autoradiographic study Brain Res. 561 1991 51 60
8. D.L. Ceulemans, M.L. Hoppenbrouwers, Y.G. Gelders, and A.J. Reyntjens The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam Pharmacopsychiatry 18 1985 303 305
9. J.P. Christianson, T. Ragole, J. Amat, B.N. Greenwood, P.V. Strong, E.D. Paul, M. Fleshner, L.R. Watkins, and S.F. Maier 5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress Biol. Psychiatry 67 2010 339 345
10. D.A. Clemett, T. Punhani, M.S. Duxon, T.P. Blackburn, and K.C. Fone Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS Neuropharmacology 39 2000 123 132
11. C.V. de Andrade Strauss, M.A. Vicente, and H. Zangrossi Jr. Activation of 5-HT1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic-like effects Behav. Brain Res. 246 2013 103 110
12. V.C. de Bortoli, R.L. Nogueira, and H. Zangrossi Jr. Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray Psychopharmacology (Berl) 183 2006 422 428
13. A.P. de Mello Cruz, G. Pinheiro, S.H. Alves, G. Ferreira, M. Mendes, L. Faria, C.E. Macedo, V. Motta, and J. Landeira-Fernandez Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze Psychopharmacology (Berl.) 182 2005 345 354
14. C.M. Del-Ben, and F.G. Graeff Panic disorder: is the PAG involved? Neural Plast 2009 10.1155/2009/108135 e-pub 10 March 2009
15. A. Drago, and A. Serretti Focus on HTR2C: a possible suggestion for genetic studies of complex disorders Am. J. Med. Genet. B. Neuropsychiatr.Genet. 150 2009 601 637
16. E. Dremencov, Y. Weizmann, N. Kinor, I. Gispan-Herman, and G. Yadid Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response Curr. Drug Targets 7 2006 165 175
17. F.G. Graeff, and H. Zangrossi Jr. Animal models of anxiety disorders H. D'Haenen, J.A. den Boer, H. Westenberg, P. Willner, Textbook of Biological Psychiatry: Animal Models of Anxiety Disorders 2002 Wiley and Sons London 879 893
18. S.D. Gleason, V.L. Lucaites, H.E. Shannon, D.L. Nelson, and J.D. Leander m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors Behav. Pharmacol 12 2001 613 620
19. B.N. Greenwood, P.V. Strong, A.B. Loughridge, H.E. Day, P.J. Clark, A. Mika, J.E. Hellwinkel, K.G. Spence, and M. Fleshner 5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise PLoS One 9 2012 e46118 10.1371/journal.pone.0046118
20. J.M. Gorman Treatment of generalized anxiety disorder J. Clin. Psychiatry 63 2002 17 23
21. L.K. Heisler, L. Zhou, P. Bajwa, J. Hsu, and L.H. Tecott Serotonin 5-HT(2C) receptors regulate anxiety-like behavior Genes Brain Behav. 6 2007 491 496
22. R.K. Jan, J.C. Lin, H. Lee, J.L. Sheridan, R.R. Kydd, I.J. Kirk, and B.R. Russell Determining the subjective effects of TFMPP in human males Psychopharmacology (Berl.) 211 2010 347 353
23. R.S. Kahn, S. Wetzler, H.M. van Praag, G.M. Asnis, and T. Strauman Behavioral indications for serotonin receptor hypersensitivity in panic disorder Psychiatry Res. 25 1988 101 104
24. G.A. Kennett, S. Lightowler, V. de Biasi, N.C. Stevens, M.D. Wood, I.F. Tulloch, and T.P. Blackburn Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function Neuropharmacology 12 1994 1581 1588
25. G.A. Kennett, P. Whitton, K. Shah, and G. Curzon Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists Eur. J. Pharmacol. 3 1989 445 454
26. G.A. Kennett, F. Bright, B. Trail, T.P. Blackburn, and G.J. Sanger Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats Neuropharmacology 36 1997 707 712
27. A. Kimura, P.L. Stevenson, R.N. Carter, G. Maccoll, K.L. French, J.P. Simons, R. Al-Shawi, V. Kelly, K.E. Chapman, and M.C. Holmes Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity Eur. J. Neurosci. 30 2009 299 306
28. C. Loane, and M. Politis Buspirone: what is it all about? Brain Res. 1461 2012 111 118
29. Q. Li, T. Luo, X. Jiang, and J. Wang Anxiolytic effects of 5-HT1A receptors and anxiogenic effects of 5-HT2C receptors in the amygdala of mice Neuropharmacology 62 2012 474 484
30. J.R. Martin, T.M. Ballard, and G.A. Higgins Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety Pharmacol. Biochem. Behav 71 2002 615 625
31. M.J. Millan The neurobiology and control of anxious states Prog. Neurobiol. 70 2003 83 244
32. M.J. Millan Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Therapie 60 2005 441 460
33. D. Mobbs, P. Petrovic, J.L. Marchant, D. Hassabis, N. Weiskopf, B. Seymour, R.J. Dolan, and C.D. Frith When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans Science 317 2007 1079 1083
34. R. Mongeau, and C.A. Marsden Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats Psychopharmacology (Berl.) 131 1997 321 328
35. R. Mongeau, C.B. Martin, C. Chevarin, R. Maldonado, M. Hamon, P. Robledo, and L. Lanfumey 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment J. Neurochem. 115 2010 438 449
36. F.A. Moreira, P.H. Gobira, T.G. Viana, M.A. Vicente, H. Zangrossi, and F.G. Graeff Modeling panic disorder in rodents Cell Tissue Res. 2013 10.1007/s00441-013-1610-1 e-pub ahead of print 13Apr 2013
37. Y.G. Ni, and R. Miledi Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac) Proc. Natl. Acad. Sci. U. S. A 94 1997 2036 2040
38. D.H. Overstreet, D.J. Knapp, R.A. Angel, M. Navarro, and G.R. Breese Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands Psychopharmacology (Berl.) 187 2006 1 12
39. D.H. Overstreet, D.J. Knapp, S.S. Moy, and G.R. Breese A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats Psychopharmacology (Berl.) 167 2003 344 352
40. E.P. Pälvimäki, B.L. Roth, H. Majasuo, A. Laakso, M. Kuoppamäki, E. Syvälahti, and J. Hietala Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor Psychopharmacology (Berl) 126 1996 234 240
41. G. Paxinos, and C. Watoson The Rat Brain in Stereotaxic Coordinates sixth ed. 2007 Elsevier Academic Press San Diego
42. S.C. Poltronieri, H. Zangrossi Jr., and M. de Barros Viana Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze Behav. Brain Res. 147 2003 185 192
43. M. Pompeiano, J.M. Palacios, and G. Mengod Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors Behav. Brain Res. 23 1994 163 178
44. D.G. Rainnie Serotonergic modulation of neurotransmission in the rat basolateral amygdala J. Neurophysiol 82 1999 69 85
45. B. Rocha, M. Rigo, G. Di Scala, G. Sandner, and D. Hoyer Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels Eur. J. Pharmacol. 262 1994 125 131
46. J. Setem, A.P. Pinheiro, V.A. Motta, S. Morato, and A.P. Cruz Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze Pharmacol. Biochem. Behav. 62 1999 515 521
47. R.C. Teixeira, H. Zangrossi, and F.G. Graeff Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety Pharmacol. Biochem. Behav. 65 2000 571 576
48. M.A. Vicente, and H. Zangrossi Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration Int. J. Neuropsychopharmacol. 15 2012 389 440
49. E.A. Walker, S.J. Kohut, R.W. Hass, E.K. Brown Jr., A. Prabandham, and T. Lefever Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice Neuropharmacology 49 2005 1210 1219
50. M. Yamauchi, T. Tatebayashi, K. Nagase, M. Kojima, and T. Imanishi Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats Pharmacol. Biochem. Behav. 78 2004 683 689
51. H. Zangrossi Jr., M.B. Viana, J. Zanoveli, C. Bueno, R.L. Nogueira, and F.G. Graeff Serotonergic regulation of inhibitory avoidance and one-way escape in the rat elevated T-maze Neurosci. Biobehav. Rev. 25 2001 637 645
52. H. Zangrossi Jr., and F.G. Graeff Behavioral validation of the elevated T-maze, a new animal model of anxiety Brain Res. Bull. 44 1997 1 5
53. J.M. Zanoveli, R.L. Nogueira, and H. Zangrossi Jr. Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety Behav. Pharmacol. 16 2005 543 552
54. J.M. Zanoveli, R.L. Nogueira, and H. Zangrossi Jr. Enhanced reactivity of 5-HT1A receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: evidence from the elevated T-maze Neuropharmacology 52 2007 1188 1195
55. J.M. Zanoveli, R.L. Pobbe, V.C. de Bortoli, M.C. Carvalho, M.L. Brandão, and H. Zangrossi Jr. Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine Int. J. Neuropsychopharmacol. 13 2010 1079 1088
56. J. Zohar, T.R. Insel, R.C. Zohar-Kadouch, J.L. Hill, and D.L. Murphy Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment Arch. Gen. Psychiatry 45 1988 167 172